Long Run Wealth Advisors LLC Increases Stake in AstraZeneca PLC $AZN

Long Run Wealth Advisors LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 43.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,812 shares of the company’s stock after acquiring an additional 1,456 shares during the quarter. Long Run Wealth Advisors LLC’s holdings in AstraZeneca were worth $336,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in AZN. SCS Capital Management LLC bought a new stake in shares of AstraZeneca in the 1st quarter valued at about $3,066,000. Robbins Farley bought a new stake in shares of AstraZeneca in the 2nd quarter valued at about $1,857,000. Jennison Associates LLC boosted its holdings in shares of AstraZeneca by 15.2% in the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after buying an additional 1,605,133 shares in the last quarter. Oliver Luxxe Assets LLC boosted its holdings in shares of AstraZeneca by 6.0% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock valued at $5,472,000 after buying an additional 4,449 shares in the last quarter. Finally, Alhambra Investment Management LLC bought a new stake in shares of AstraZeneca in the 2nd quarter valued at about $320,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

NASDAQ:AZN opened at $81.15 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a market cap of $251.68 billion, a price-to-earnings ratio of 30.51, a price-to-earnings-growth ratio of 1.52 and a beta of 0.36. The company has a 50 day moving average price of $81.24 and a 200-day moving average price of $75.32. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $86.57.

Analyst Ratings Changes

A number of research firms recently commented on AZN. Jefferies Financial Group began coverage on shares of AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating for the company. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research note on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.